期刊
SMALL
卷 18, 期 25, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202200673
关键词
biodistribution; cancer; molecular imaging; peptide receptor radionuclide therapy; toxicity
类别
资金
- German Research Foundation [DFG: GRK/RTG 2375, 331065168]
Endogenous targeted radiotherapy has side effects, and the use of nanocarriers can mitigate these effects. Nanocarriers have advantages of prolonging circulation time, increasing tumor retention, and offering multifunctionality for targeting strategies.
Endogenous targeted radiotherapy is emerging as an integral modality to treat a variety of cancer entities. Nevertheless, despite the positive clinical outcome of the treatment using radiolabeled peptides, small molecules, antibodies, and nanobodies, a high degree of hepatotoxicity and nephrotoxicity still persist. This limits the amount of dose that can be injected. In an attempt to mitigate these side effects, the use of nanocarriers such as nanoparticles (NPs), dendrimers, micelles, liposomes, and nanogels (NGs) is currently being explored. Nanocarriers can prolong circulation time and tumor retention, maximize radiation dosage, and offer multifunctionality for different targeting strategies. In this review, the authors first provide a summary of radiation therapy and imaging and discuss the new radiotracers that are used preclinically and clinically. They then highlight and identify the advantages of radio-nanomedicine and its potential in overcoming the limitations of endogenous radiotherapy. Finally, the review points to the ongoing efforts to maximize the use of radio-nanomedicine for efficient clinical translation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据